Canadian women will no longer have access to Premarin, a menopause medication made in Canada, even though its manufacturer plans to keep producing it for patients in the United States. Pfizer has discontinued the Premarin estrogen tablets and vaginal cream in Canada, products used for decades to treat hot flashes, night sweats, vaginal burning and dryness, abnormal uterine bleeding and the prevention of osteoporosis.

The active ingredient, conjugated equine estrogen, is derived from the urine of pregnant mares collected on 12 family-owned ranches in Manitoba and Saskatchewan since the early 1940s. Pfizer stopped selling the vaginal cream to Canadians in early November, citing « business reasons ». The company says the tablets will be withdrawn from the Canadian market starting next June.

Sophie Morin, senior communications manager at Pfizer Canada, said the products had become « commercially unsustainable » for the company to keep supplying in Canada. Morin said the decision was not « driven solely by the pricing conditions for Premarin in Canada ». She cited manufacturing and supply costs, the pricing and reimbursement environment, and the ability to maintain a sustainable supply over the longer term.

The price gap between the two countries has drawn criticism. Dr. Jennifer Gunter, a gynecologist from Manitoba who now practises in the United States, wrote on her Substack that a tube of Premarin cream costs about C$50 in Canada, while the same tube sells for roughly US$400 to US$500 in the United States. « This isn’t just about Premarin. Every Canadian who cares about access to medications needs to be engaged and speak up, » Gunter wrote.

Menopause specialist Dr. Michelle Jacobson said it feels wrong that she will no longer be able to prescribe Premarin to her patients, given that the drug originates in Canada. « Globally, it is, the supply chain starts in Canada, and yet, for reasons that are not completely transparent, Canadians are now not going to be able to access this homegrown raw material, » Jacobson said.

Provincial drug plans are responding unevenly. Some public plans, including Ontario’s, covered Pfizer’s Premarin cream but not the alternative cream on the market. Lily Barnes, a spokesperson for the Ontario Ministry of Health, said the province’s drug benefits include other estrogen products, such as a vaginal ring, tablet and insert. Dr. Jacobson disputed that these are equivalent, noting that the active ingredients differ, and said the vaginal cream can also work better for certain conditions, such as dryness.

Alberta’s Ministry of Health said that, as a result of Pfizer’s decision, it is adding Estragyn vaginal cream, made by Searchlight Pharma, to the province’s drug benefit list so women continue to have access. A spokesperson described the step as temporary, with a plan to make it permanent. Quebec and Manitoba’s provincial drug benefit plans already cover the alternative.

12Views